INmune Bio, Inc. (NASDAQ:INMB) Short Interest Update

INmune Bio, Inc. (NASDAQ:INMB) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 3,020,000 shares, an increase of 8.6% from the August 15th total of 2,780,000 shares. Based on an average daily volume of 181,700 shares, the short-interest ratio is presently 16.6 days. Approximately 22.5% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, Scotiabank assumed coverage on INmune Bio in a research note on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 target price for the company.

Insider Buying and Selling

In related news, Director Scott Juda acquired 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The stock was acquired at an average cost of $7.27 per share, with a total value of $36,350.00. Following the completion of the purchase, the director now directly owns 71,603 shares in the company, valued at $520,553.81. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other INmune Bio news, CFO David J. Moss bought 7,690 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was purchased at an average cost of $6.38 per share, with a total value of $49,062.20. Following the completion of the purchase, the chief financial officer now owns 1,275,869 shares in the company, valued at $8,140,044.22. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Scott Juda bought 5,000 shares of the firm’s stock in a transaction on Tuesday, June 25th. The stock was acquired at an average cost of $7.27 per share, with a total value of $36,350.00. Following the completion of the purchase, the director now owns 71,603 shares of the company’s stock, valued at approximately $520,553.81. The disclosure for this purchase can be found here. Insiders purchased a total of 28,070 shares of company stock valued at $183,537 over the last three months. Company insiders own 35.20% of the company’s stock.

Institutional Trading of INmune Bio

A number of institutional investors have recently modified their holdings of INMB. CVI Holdings LLC bought a new stake in INmune Bio during the second quarter worth about $5,260,000. Marshall Wace LLP raised its holdings in INmune Bio by 332.1% during the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after acquiring an additional 89,091 shares in the last quarter. Rhumbline Advisers bought a new stake in INmune Bio during the second quarter worth about $121,000. Bank of New York Mellon Corp raised its holdings in INmune Bio by 124.6% during the second quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after acquiring an additional 32,511 shares in the last quarter. Finally, Westside Investment Management Inc. raised its holdings in INmune Bio by 31.8% during the second quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock worth $400,000 after acquiring an additional 10,950 shares in the last quarter. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Trading Down 6.5 %

Shares of INmune Bio stock traded down $0.36 during trading on Wednesday, reaching $5.19. The stock had a trading volume of 474,980 shares, compared to its average volume of 145,573. The company has a market capitalization of $102.67 million, a price-to-earnings ratio of -2.70 and a beta of 1.86. The stock has a fifty day moving average price of $7.35 and a two-hundred day moving average price of $9.14. INmune Bio has a 52 week low of $5.18 and a 52 week high of $14.74.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.